全文获取类型
收费全文 | 292539篇 |
免费 | 25221篇 |
国内免费 | 11601篇 |
专业分类
耳鼻咽喉 | 1630篇 |
儿科学 | 9973篇 |
妇产科学 | 2976篇 |
基础医学 | 31228篇 |
口腔科学 | 4831篇 |
临床医学 | 29693篇 |
内科学 | 64444篇 |
皮肤病学 | 3674篇 |
神经病学 | 29092篇 |
特种医学 | 8011篇 |
外国民族医学 | 34篇 |
外科学 | 27734篇 |
综合类 | 45962篇 |
现状与发展 | 52篇 |
一般理论 | 11篇 |
预防医学 | 20494篇 |
眼科学 | 3373篇 |
药学 | 20807篇 |
199篇 | |
中国医学 | 13588篇 |
肿瘤学 | 11555篇 |
出版年
2024年 | 307篇 |
2023年 | 5296篇 |
2022年 | 7168篇 |
2021年 | 13551篇 |
2020年 | 13416篇 |
2019年 | 10797篇 |
2018年 | 10521篇 |
2017年 | 10741篇 |
2016年 | 11357篇 |
2015年 | 11057篇 |
2014年 | 19981篇 |
2013年 | 22453篇 |
2012年 | 16932篇 |
2011年 | 18943篇 |
2010年 | 15126篇 |
2009年 | 14595篇 |
2008年 | 14860篇 |
2007年 | 14778篇 |
2006年 | 13527篇 |
2005年 | 11638篇 |
2004年 | 10084篇 |
2003年 | 8691篇 |
2002年 | 7422篇 |
2001年 | 6563篇 |
2000年 | 5376篇 |
1999年 | 4435篇 |
1998年 | 3780篇 |
1997年 | 3202篇 |
1996年 | 2691篇 |
1995年 | 2770篇 |
1994年 | 2462篇 |
1993年 | 1990篇 |
1992年 | 1843篇 |
1991年 | 1609篇 |
1990年 | 1282篇 |
1989年 | 1077篇 |
1988年 | 953篇 |
1987年 | 862篇 |
1986年 | 739篇 |
1985年 | 868篇 |
1984年 | 719篇 |
1983年 | 437篇 |
1982年 | 528篇 |
1981年 | 441篇 |
1980年 | 329篇 |
1979年 | 299篇 |
1978年 | 224篇 |
1977年 | 196篇 |
1976年 | 165篇 |
1975年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
71.
目的筛选成骨型骨肉瘤与正常成骨细胞的差异表达基因, 寻找成骨型骨肉瘤发生、发展的关键基因。方法从Gene Expression Omnibus(GEO)数据库获得正常成骨细胞和骨肉瘤组织的基因表达数据集GSE33382, 采用R语言的limma包筛选正常成骨细胞和成骨型骨肉瘤的差异表达基因, 对差异表达基因进行京都基因与基因组百科全书(KEGG)通路富集分析。采用String数据库构建蛋白交互网络, 应用Cytoscape软件的分子复合物检测(MCODE)插件筛选互作网络中的网络模块, 应用Cytoscape软件中的BiNGO模块对MCODE筛选得到的前3个主要模块所包含的差异表达基因进行基因本体(GO)富集分析。采用MCC算法筛选蛋白互作网络中前10个关键基因。从GEO数据库获得骨肉瘤的基因表达和生存数据集GSE39055, 采用Kaplan-Meier法进行生存分析。选取2005年1月至2015年12月福建医科大学附属第一医院收治的48例成骨型骨肉瘤患者的资料进行验证, 采用免疫组化法测定骨肉瘤组织中STC2蛋白的表达, 结合患者的临床资料进行生存分析。结果从GSE33382数据集... 相似文献
72.
《Clinical colorectal cancer》2022,21(2):71-79
In recent years, studies on the molecular typing of colorectal cancer have matured, and the V-raf murine sarcoma viral oncogene homolog B (BRAF) of the mitogen-activated protein kinase pathway has been shown to be an important effector molecule of this pathway and regulates the occurrence and development of colorectal cancer. Clinical observations indicate that colorectal cancer patients harboring the BRAF V600E mutation have a worse prognosis than BRAF wild type patients. Several resistance mechanisms have been identified that have led to the development of different treatment strategies, which have shown encouraging activity in early clinical trials. Therefore, a reasonable combination of targeted therapies is expected to further enhance the efficacy of selective BRAF inhibitors. Moreover, some CRC patients with high microsatellite instability or a mismatch repair deficiency seem to be susceptible to checkpoint inhibitors with objective and sustained clinical responses, providing new opportunities for patients with advanced disease. This article primarily explores 3 aspects of the treatment strategies for advanced BRAF-mutated colorectal cancer; chemotherapy, targeted therapy, and immunotherapy. 相似文献
73.
74.
75.
76.
77.
78.
79.
80.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献